Contrast-enhanced ultrasound may avert prostate biopsies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies.

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies. They found generally that contrast ultrasound provided more precise locational information than is available with unenhanced grayscale ultrasound. Biopsies based on the contrast scans resulted in a sensitivity of 85.2%, according to the group from the Medical University of Innsbruck (European Congress of Radiology 2009 abstract C-390).

A group at Shanghai’s Jio Tong University used microflow imaging and found a sensitivity of 80% and an accuracy of 83% for this contrast strategy. However, limitations included cost and training (abstract C-391).

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content